美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

2倍做多NVO ETF-Defiance

18.46

+0.16000.87%

成交量：10.56萬

成交額：194.00萬

市值：5,165.29萬

市盈率：- -

高：18.57

開：18.38

低：18.25

收：18.30

52周最高：105.60

52周最低：14.59

股本：279.81萬

流通股本：279.81萬

量比：1.25

換手率：3.77%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

劍指全球市場！諾和諾德(NVO.US)擴建愛爾蘭工廠欲藉口服版Wegovy搶佔市場份額

貝倫貝格：將諾和諾德目標價下調至360丹麥克朗

2026年，這22款藥物值得關注

德銀：諾和諾德仍有機會重新把握肥胖症市場的機遇

环球市场播报

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/NVOX"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVOX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","market":"US","secType":"STK","nameCN":"2倍做多NVO ETF-Defiance","latestPrice":18.46,"timestamp":1770908469008,"preClose":18.3,"halted":0,"volume":105555,"delay":0,"changeRate":0.00874316939890711,"floatShares":2798101,"shares":2798101,"eps":0,"marketStatus":"交易中","change":0.16,"latestTime":"02-12 10:01:12 EST","open":18.38,"high":18.57,"low":18.25,"amount":1939994.7116699999,"amplitude":0.017486,"askPrice":18.51,"askSize":1020,"bidPrice":18.47,"bidSize":780,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1770930000000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":18.3,"sharesOutstanding":2798101,"nav":18.62,"aum":52100640.62,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":18.46,"preClose":18.3,"latestTime":"09:27 EST","volume":8142,"amount":150488.691846,"timestamp":1770906469280,"change":0.16,"changeRate":0.008743,"amplitude":0.016421},"postHourTrading":{"tag":"盘后","latestPrice":18.35,"preClose":18.3,"latestTime":"19:57 EST","volume":9728,"amount":178409.5812,"timestamp":1770857876866,"change":0.05,"changeRate":0.002732,"amplitude":0.012749},"volumeRatio":1.245296,"impliedVol":0.8824,"impliedVolPercentile":0.568},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","floatShares":2798101,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.245296,"shares":2798101,"dividePrice":0,"high":18.57,"amplitude":0.017486,"preClose":18.3,"low":18.25,"week52Low":14.5902,"pbRate":"--","week52High":105.6,"institutionHeld":0,"latestPrice":18.46,"committee":-0.133333,"eps":0,"divideRate":0,"volume":105555,"delay":0,"ttmEps":0,"open":18.38,"prevYearClose":21.89,"prevWeekClose":17.59,"prevMonthClose":28.89,"prevQuarterClose":21.89,"fiveDayClose":14.7,"twentyDayClose":28.94,"sixtyDayClose":20.48},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-12-09","symbol":"NVOX","defaultRemindTime":1765290600000,"type":"split","dateTimestamp":1765256400000,"forFactor":8,"toFactor":1,"ratio":8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOX\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610794788","title":"劍指全球市場！諾和諾德(NVO.US)擴建愛爾蘭工廠 欲藉口服版Wegovy搶佔市場份額","url":"https://stock-news.laohu8.com/highlight/detail?id=2610794788","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610794788?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 18:57","pubTimestamp":1770893858,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺和诺德计划加大在爱尔兰的投资，在当地生产其畅销减肥药Wegovy的口服版本，以供应美国以外的市场。诺和诺德首席执行官迈克·杜斯达尔表示，诺和诺德将扩建其位于爱尔兰中部阿斯隆的生产设施。杜斯达尔称，Wegovy口服药于1月初上市，成为有史以来最成功的药品首发之一，目前已有超过24万名美国患者服用。爱尔兰是全球制药制造中心之一。礼来在当地生产其重磅减肥和糖尿病药物的活性成分。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404784.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"剑指全球市场！诺和诺德(NVO.US)扩建爱尔兰工厂 欲借口服版Wegovy抢占市场份额","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NVOX","LU0154236417.USD","NVOH","BK4007","IE00BKVL7J92.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD","NVO","BK4532","BK4588","BK4585","BK4599","LU1093756168.USD"],"gpt_icon":0},{"id":"2610197339","title":"貝倫貝格：將諾和諾德目標價下調至360丹麥克朗","url":"https://stock-news.laohu8.com/highlight/detail?id=2610197339","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610197339?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 14:27","pubTimestamp":1770877621,"startTime":"0","endTime":"0","summary":"贝伦贝格将诺和诺德目标价从415丹麦克朗下调至360丹麦克朗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260212/32014623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4585","BK4588","BK4007","NVOX","BK4599","LU0154236417.USD","NVO","IE00BZ1G4Q59.USD","LU1093756168.USD","IE00BKVL7J92.USD","NVOH","LU1093756325.SGD","BK4532"],"gpt_icon":0},{"id":"2610150992","title":"2026年，這22款藥物值得關注","url":"https://stock-news.laohu8.com/highlight/detail?id=2610150992","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610150992?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 11:27","pubTimestamp":1770866876,"startTime":"0","endTime":"0","summary":"目前，礼来已正式提交该药物的上市申请，有望在2026年实现获批。该药物的III期REDEFINE 4研究结果预计于2026年上半年揭晓。FDA预计将于2026年完成该药物的审评工作。2026年第一季度，预计辉瑞将公布MET-0971的IIb期临床试验数据。02肿瘤领域根据FirstWord Pharma，2026年，肿瘤领域有7款关键药物值得关注。吉利德计划于2026年在","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212113614a6f1834d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212113614a6f1834d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BKVL7J92.USD","LU0154236417.USD","BK4007","NVO","BK4532","BK4585","NVOX","IE00BZ1G4Q59.USD","NVOH","LU1093756168.USD","BK4588","LU1093756325.SGD","BK4599"],"gpt_icon":0},{"id":"2610935665","title":"德銀：諾和諾德仍有機會重新把握肥胖症市場的機遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2610935665","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610935665?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 18:28","pubTimestamp":1770805680,"startTime":"0","endTime":"0","summary":"德意志银行分析师Emmanuel Papadakis写道，诺和诺德在适当的时候仍有机会重新把握其在肥胖症市场的机遇。该行仍对诺和诺德持乐观看法，该股市盈率已回落至十几倍的水平。　　该公司Wegovy口服药的上市表现稳健，下半年有潜在的销量利好因素，而且或许最重要的是，关键的cagrisema数据仍有待公布。　　该行将该股目标价从475丹麦克朗下调至400丹麦克朗，并维持买入评级。该股下跌2.4%，至307.55丹麦克朗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-11/doc-inhmmvza3702737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4588","NVOX","NVOH","BK4532","IE00BKVL7J92.USD","LU0154236417.USD","BK4599","NVO","BK4007","LU1093756168.USD","BK4585"],"gpt_icon":0}],"pageSize":4,"totalPage":18,"pageCount":1,"totalSize":72,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NVOX\",params:#limit:6,delay:false,,,undefined,":[]}}